<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36787921</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2053-8790</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Lupus science &amp; medicine</Title><ISOAbbreviation>Lupus Sci Med</ISOAbbreviation></Journal><ArticleTitle>Risks of mortality and severe coronavirus disease 19 (COVID-19) outcomes in patients with or without systemic lupus erythematosus.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e000750</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/lupus-2022-000750</ELocationID><Abstract><AbstractText Label="OBJECTIVES">We compared the outcomes of patients with or without systemic lupus erythematosus (SLE) who were diagnosed with coronavirus disease 19 (COVID-19) and evaluated factors within patients with SLE associated with severe outcomes.</AbstractText><AbstractText Label="METHODS">This retrospective cohort study used the deidentified Optum COVID-19 electronic health record dataset to identify patients with COVID-19 from 1/1/2020 to 31/12/2020. Cases with SLE were matched with general controls at a ratio of 1:10 by age, sex, race and ethnicity and COVID-19 diagnosis date. Outcomes included 30-day mortality, mechanical ventilation, hospitalisation and intensive care unit admission. We evaluated the relationship between COVID-19-related outcomes and SLE using multivariable logistic regression. In addition, within SLE cases, we examined factors associated with COVID-19 related outcomes, including disease activity and SLE therapy.</AbstractText><AbstractText Label="RESULTS">We included 687 patients matched with 6870 controls. Unadjusted rates of outcomes for patients with SLE were significantly worse than for matched controls including mortality (3.6% vs 1.8%), mechanical ventilation (6% vs 2.5%) and hospitalisation (31% vs 17.7%) (all p&lt;0.001). After multivariable adjustment, patients with SLE had increased risks of mechanical ventilation (OR 1.81, 95%&#x2009;CI 1.16 to 2.82) and hospitalisation (OR 1.32, 95%&#x2009;CI 1.05 to 1.65). Among patients with SLE, severe disease activity was associated with increased risks of mechanical ventilation (OR 5.83, 95%&#x2009;CI 2.60 to 13.07) and hospitalisation (OR 3.97, 95%&#x2009;CI 2.37 to 6.65). Use of glucocorticoids, mycophenolate and tacrolimus before COVID-19 was associated with worse outcomes.</AbstractText><AbstractText Label="CONCLUSION">Patients with SLE had increased risk of severe COVID-19-related outcomes compared with matched controls. Patients with severe SLE disease activity or prior use of corticosteroids experienced worse outcomes.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bruera</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3027-9287</Identifier><AffiliationInfo><Affiliation>Section of Allergy, Immunology, and Rheumatology, Baylor College of Medicine, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lei</LastName><ForeName>Xiudong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yazdany</LastName><ForeName>Jinoos</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3508-4094</Identifier><AffiliationInfo><Affiliation>University of California at San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chavez-MacGregor</LastName><ForeName>Mariana</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giordano</LastName><ForeName>Sharon H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suarez-Almazor</LastName><ForeName>Maria E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA msalmazor@mdanderson.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AR070155</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus Sci Med</MedlineTA><NlmUniqueID>101633705</NlmUniqueID><ISSNLinking>2053-8790</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antirheumatic Agents</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Systemic Lupus Erythematosus</Keyword></KeywordList><CoiStatement>Competing interests: MES-A has received consultant fees from participation on advisory boards for Gilead, Avenue Therapeutics, ChemoCentryx, is a current member of advisory board for Celgene and all activities are unrelated to this work. JY has research grants from Astra Zeneca, Gilead and the Bristol Myers Squibb Foundation. She has performed consulting for Aurinia, Astra Zeneca and Pfizer, unrelated to this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>14</Day><Hour>20</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36787921</ArticleId><ArticleId IdType="pmc">PMC9929928</ArticleId><ArticleId IdType="doi">10.1136/lupus-2022-000750</ArticleId><ArticleId IdType="pii">10/1/e000750</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Curtis JR, Zhou X, Rubin DT, et al. . Characteristics, comorbidities, and outcomes of SARS-cov-2 infection in patients with autoimmune conditions treated with systemic therapies: a population-based study. J Rheumatol 2022;49:320&#x2013;9. 10.3899/jrheum.210888</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.210888</ArticleId><ArticleId IdType="pubmed">34782447</ArticleId></ArticleIdList></Reference><Reference><Citation>Sattui SE, Conway R, Putman MS, et al. . Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 global rheumatology alliance physician registry: a retrospective cohort study. Lancet Rheumatol 2021;3:e855&#x2013;64. 10.1016/S2665-9913(21)00316-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00316-7</ArticleId><ArticleId IdType="pmc">PMC8570701</ArticleId><ArticleId IdType="pubmed">34778843</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugarte-Gil MF, Alarc&#xf3;n GS, Izadi Z, et al. . Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 global rheumatology alliance. Ann Rheum Dis 2022;81:970&#x2013;8. 10.1136/annrheumdis-2021-221636</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221636</ArticleId><ArticleId IdType="pmc">PMC8882632</ArticleId><ArticleId IdType="pubmed">35172961</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Silva KM, Jorge A, Cohen A, et al. . COVID-19 outcomes in patients with systemic autoimmune rheumatic diseases compared to the general population: a US multicenter, comparative cohort study. Arthritis Rheumatol 2021;73:914&#x2013;20. 10.1002/art.41619</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41619</ArticleId><ArticleId IdType="pmc">PMC8169514</ArticleId><ArticleId IdType="pubmed">33305544</ArticleId></ArticleIdList></Reference><Reference><Citation>Izadi Z, Brenner EJ, Mahil SK, et al. . Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and COVID-19. JAMA Netw Open 2021;4:e2129639. 10.1001/jamanetworkopen.2021.29639</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.29639</ArticleId><ArticleId IdType="pmc">PMC8524310</ArticleId><ArticleId IdType="pubmed">34661663</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianfrancesco M, Hyrich KL, Al-Adely S, et al. . Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis 2020;79:859&#x2013;66. 10.1136/annrheumdis-2020-217871</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217871</ArticleId><ArticleId IdType="pmc">PMC7299648</ArticleId><ArticleId IdType="pubmed">32471903</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmajuk G, Montgomery AD, Leonard S, et al. . Factors associated with hospitalization and death after COVID-19 diagnosis among patients with rheumatic disease: an analysis of Veterans Affairs data. ACR Open Rheumatol 2021;3:796&#x2013;803. 10.1002/acr2.11328</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr2.11328</ArticleId><ArticleId IdType="pmc">PMC8593772</ArticleId><ArticleId IdType="pubmed">34423917</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama S, Hamdeh S, Micic D, et al. . Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis 2021;80:384&#x2013;91. 10.1136/annrheumdis-2020-218946</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218946</ArticleId><ArticleId IdType="pubmed">33051220</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S, Hayek SS, Wang W, et al. . Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. JAMA Intern Med 2020;180:1436&#x2013;47. 10.1001/jamainternmed.2020.3596</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.3596</ArticleId><ArticleId IdType="pmc">PMC7364338</ArticleId><ArticleId IdType="pubmed">32667668</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, et al. . The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007;147:573&#x2013;7. 10.7326/0003-4819-147-8-200710160-00010</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-147-8-200710160-00010</ArticleId><ArticleId IdType="pubmed">17938396</ArticleId></ArticleIdList></Reference><Reference><Citation>Klabunde CN, Potosky AL, Legler JM, et al. . Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000;53:1258&#x2013;67. 10.1016/s0895-4356(00)00256-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0895-4356(00)00256-0</ArticleId><ArticleId IdType="pubmed">11146273</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlson ME, Pompei P, Ales KL, et al. . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373&#x2013;83. 10.1016/0021-9681(87)90171-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0021-9681(87)90171-8</ArticleId><ArticleId IdType="pubmed">3558716</ArticleId></ArticleIdList></Reference><Reference><Citation>Speyer CB, Li D, Guan H, et al. . Comparison of an administrative algorithm for SLE disease severity to clinical SLE disease activity index scores. Rheumatol Int 2020;40:257&#x2013;61. 10.1007/s00296-019-04477-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-019-04477-4</ArticleId><ArticleId IdType="pmc">PMC6960319</ArticleId><ArticleId IdType="pubmed">31784790</ArticleId></ArticleIdList></Reference><Reference><Citation>Raiker R, Pakhchanian H, DeYoung C, et al. . Short term outcomes of COVID-19 in lupus: propensity score matched analysis from a nationwide multi-centric research network. J Autoimmun 2021;125:102730. 10.1016/j.jaut.2021.102730</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2021.102730</ArticleId><ArticleId IdType="pmc">PMC8501265</ArticleId><ArticleId IdType="pubmed">34649723</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertoglio IM, Valim JM de L, Daffre D, et al. . Poor prognosis of COVID-19 acute respiratory distress syndrome in lupus erythematosus: nationwide cross-sectional population study of 252 119 patients. ACR Open Rheumatol 2021;3:804&#x2013;11. 10.1002/acr2.11329</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr2.11329</ArticleId><ArticleId IdType="pmc">PMC8593786</ArticleId><ArticleId IdType="pubmed">34423922</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparks JA, Wallace ZS, Seet AM, et al. . Associations of baseline use of biologic or targeted synthetic dmards with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry. Ann Rheum Dis 2021;80:1137&#x2013;46. 10.1136/annrheumdis-2021-220418</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220418</ArticleId><ArticleId IdType="pmc">PMC8172266</ArticleId><ArticleId IdType="pubmed">34049860</ArticleId></ArticleIdList></Reference><Reference><Citation>Mageau A, Papo T, Ruckly S, et al. . Survival after COVID-19-associated organ failure among inpatients with systemic lupus erythematosus in france: a nationwide study. Ann Rheum Dis 2022;81:569&#x2013;74. 10.1136/annrheumdis-2021-221599</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221599</ArticleId><ArticleId IdType="pubmed">34893471</ArticleId></ArticleIdList></Reference><Reference><Citation>Mill&#xe1;n-Guerrero RO, Caballero-Hoyos R, Mon&#xe1;rrez-Espino J. Poverty and survival from COVID-19 in mexico. J Public Health (Oxf) 2021;43:437&#x2013;44. 10.1093/pubmed/fdaa228</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/pubmed/fdaa228</ArticleId><ArticleId IdType="pmc">PMC7798985</ArticleId><ArticleId IdType="pubmed">33367803</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombo FR, Alicandro G, La Vecchia C. Area-level indicators of income and total mortality during the COVID-19 pandemic. Eur J Public Health 2021;31:625&#x2013;9. 10.1093/eurpub/ckab038</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurpub/ckab038</ArticleId><ArticleId IdType="pmc">PMC8083668</ArticleId><ArticleId IdType="pubmed">33749735</ArticleId></ArticleIdList></Reference><Reference><Citation>Magesh S, John D, Li WT, et al. . Disparities in COVID-19 outcomes by race, ethnicity, and socioeconomic status: a systematic-review and meta-analysis. JAMA Netw Open 2021;4:e2134147. 10.1001/jamanetworkopen.2021.34147</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.34147</ArticleId><ArticleId IdType="pmc">PMC8586903</ArticleId><ArticleId IdType="pubmed">34762110</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>